摘要
Carlos Chagas发现克氏锥虫(克氏锥虫)为一种被忽视的热带病南美锥虫病的病原体(CD),对社会经济、流行病学和人类健康的影响已经一个多世纪了。目前,只有两种商品化药物硝呋莫司和苄硝唑,治疗急性期CD,存在一些不良的副作用。因此,迫切需要新的口服和安全的药物来治疗这种寄生虫感染。在新的药物发现计划中非常重要的一个策略是基于搜索能够干扰参与克氏锥虫新陈代谢的酶的分子。 该综述将重点关注两种最有希望的治疗CD的锥虫硫酸还原酶(TR)和含铁超氧化物歧化酶(Fe-SOD)的靶标,它们可以保护寄生虫免受活性氧的氧化损伤。本文将讨论其功能,作用机制和T. cruzi TR与Fe-SOD之间的活性位点及其类似物在人类谷胱甘肽还原酶(GR)和相应的SOD中的酶的简要比较。 该综述还将总结报道的新型化合物对选择性抑制这些靶标的能力的最新发展和结构 - 活性关系,旨在确定寻找新的有效治疗CD的分子基础。
关键词: 南美锥虫病、克氏锥虫、锥虫胱甘肽还原酶、超氧化物歧化酶活性、氢溴酸、药物靶点,药物开发,构效关系。
Current Medicinal Chemistry
Title:Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease
Volume: 24 Issue: 11
关键词: 南美锥虫病、克氏锥虫、锥虫胱甘肽还原酶、超氧化物歧化酶活性、氢溴酸、药物靶点,药物开发,构效关系。
摘要: It has been over a century since Carlos Chagas discovered the Trypanosoma cruzi (T. cruzi) as the causative agent of Chagas disease (CD), a neglected tropical disease with several socioeconomic, epidemiological and human health repercussions. Currently, there are only two commercialized drugs to treat CD in acute phase, nifurtimox and benznidazol, with several adverse side effects. Thus, new orally available and safe drugs for this parasitic infection are urgently required. One strategy of great importance in new drug discovery programmes is based on the search of molecules enabling to interfere with enzymes involved in T. cruzi metabolism. This review will focus on two of the most promising targets for the therapy of CD: trypanothione reductase (TR) and the iron-containing superoxide dismutase (Fe- SOD), which protect the parasite against oxidative damage by reactive oxygen species. A brief comparison of the function, mechanism of action and the active sites between T. cruzi TR and Fe-SOD with their analogues enzymes in human, glutathione reductase (GR) and the corresponding SODs, will be discussed. This review will also summarize the recent development and structure-activity relationships of novel compounds reported for their ability to selectively inhibit these targets, aiming to define molecular bases in the search for new effective treatment of CD.
Export Options
About this article
Cite this article as:
Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease, Current Medicinal Chemistry 2017; 24 (11) . https://dx.doi.org/10.2174/0929867323666161227094049
DOI https://dx.doi.org/10.2174/0929867323666161227094049 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dopamine and Vascular Dynamics Control: Present Status and Future Perspectives
Current Neurovascular Research Nitric Oxide in the Dorsal Medulla Modulates Excitatory Somatosympathetic Reflexes
Current Cardiology Reviews “Seeing is Believing”: Perspectives of Applying Imaging Technology in Discovery Toxicology
Combinatorial Chemistry & High Throughput Screening Vasoproliferation and Antiproliferative Treatment Options in Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery TRP Channels as A Newly Emerging Non-Voltage-Gated Ca2+ Entry Channel Superfamily
Current Pharmaceutical Design Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies
Current Alzheimer Research Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology New Inotropic Pharmacologic Strategies Targeting the Failing Myocardiumin the Newborn and Infant
Mini-Reviews in Medicinal Chemistry Insulin Resistance and Hypertension
Current Hypertension Reviews P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds Snake Venom Proteins Isolated from Tunisian Vipers: Pharmacological and Therapeutic Overview
Venoms and Toxins Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer’s Disease
Current Alzheimer Research Canagliflozin : A New Hope in the Antidiabetic Armamentarium
Recent Patents on Cardiovascular Drug Discovery Novel PET Tracers in the Management of Cardiac Sarcoidosis
Current Radiopharmaceuticals Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Trends in Mitochondrial Therapeutics for Neurological Disease
Current Medicinal Chemistry